Cancers (Apr 2023)

Adjuvant Therapy for Elderly Breast Cancer Patients after Breast-Conserving Surgery: Outcomes in Real World Practice

  • Paul Rogowski,
  • Stephan Schönecker,
  • Dinah Konnerth,
  • Annemarie Schäfer,
  • Montserrat Pazos,
  • Aurélie Gaasch,
  • Maximilian Niyazi,
  • Edwin Boelke,
  • Christiane Matuschek,
  • Jan Haussmann,
  • Michael Braun,
  • Martin Pölcher,
  • Rachel Würstlein,
  • Nadia Harbeck,
  • Claus Belka,
  • Stefanie Corradini

DOI
https://doi.org/10.3390/cancers15082334
Journal volume & issue
Vol. 15, no. 8
p. 2334

Abstract

Read online

We aimed to evaluate the standard of care of adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) in elderly female patients (≥65 years) treated outside of clinical trials and to identify potential factors related to the omission of RT and the interaction with endocrine therapy (ET). All women treated with BCS at two major breast centers between 1998 and 2014 were evaluated. Data were provided by the Tumor Registry Munich. Survival analyses were conducted using the Kaplan–Meier method. Prognostic factors were identified using multivariate Cox regression analysis. The median follow-up was 88.4 months. Adjuvant RT was performed in 82% (2599/3171) of patients. Irradiated patients were younger (70.9 vs. 76.5 years, p p p = 0.014). Non-irradiated patients more often had non-invasive DCIS tumors (pTis: 20.3% vs. 6.8%, p p p p p p = 0.003). Similarly, RT alone had significantly better locoregional control rates compared to ET alone (10-year LRFS 92.6% with RT alone vs. 78.1% with ET alone, p p = 0.014). The present work confirms the efficacy of postoperative RT for breast carcinoma in elderly patients (≥65 years) treated in a modern clinical setting outside of clinical trials, even in patients who receive ET.

Keywords